Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cabaletta Bio Inc (CABA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.28-9.86%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CABA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Expand clinical development of rese-cel in multiple indications | Cabaletta Bio advances clinical development of rese-cel with positive data. | Intact | clinical development stalls or key trials fail to advance | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CABA is a high-risk clinical-stage biotechnology company, not an established earnings compounder. Its long-term thesis is in a watch state: key trial and filing plans are progressing, while recent performance trails its industry cohort.
The evidence snapshot provides no valuation measure or direct account of market expectations, so whether CABA is cheap or expensive versus peers is unclear. Its recent price reaction was down, but the evidence does not show what expectations that move reflects.
Near term, CABA remains loss-making, with a higher miss risk tied to its small size and the industry's high miss rate. Management reports progress toward rese-cel milestones, including myositis data expected in mid-2027 and a planned 2H27 filing, while outpatient and manufacturing work is mixed.
The multi-year thesis hinges on trial progress, useful clinical data, and execution on the planned filing and commercial manufacturing. Near-term sector support could strengthen if bellwethers keep reporting well, or fade if they miss or lower guidance; weakening jobs data is another stated risk.
Over the next 1 to 3 years, the setup combines progress on important development goals with substantial clinical, execution, and financial uncertainty. The evidence is low confidence and supports a watch-state thesis, not a clear fundamental resolution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating income loss was $44.3M in 2026-Q1, slightly worse than $42.6M in 2025-Q4 but shows management focus. |
| Broken |
| operating loss worsens beyond -$44.3M or fails to improve |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Results • Research and development expenses were $44.4 million for the three months ended June 30, 2026, compared to $37.6 million for the same period in 2025.” “• General and administrative expenses were $7.6 million for the three months ended June 30, 2026, compared to $8.3 million for the same period in 2025.” Delivery assessment Nov 4, 2026 |
Engage in strategic partnerships to enhance growth | Strategic partnerships support growth. | Intact | loss or failure of key partnerships | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.42 → $-1.20 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.42 | $0 | 5 / 7 |
| 2026-07-25 | $-1.42 | $0 | 5 / 7 |
| 2026-07-26 | $-1.42 | $0 | 5 / 7 |
| 2026-07-27 | $-1.42 | $0 | 5 / 7 |
| 2026-07-28 | $-1.42 | $0 | 5 / 7 |
| 2026-07-29 | $-1.42 | $0 | 5 / 7 |
| 2026-07-30 | $-1.42 | $0 | 5 / 7 |
| 2026-07-31 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-01 | $-1.42 | $0 | 5 / 7 |
| 2026-08-02 | $-1.42 | $0 | 5 / 7 |
| 2026-08-03 | $-1.42 | $0 | 5 / 7 |
| 2026-08-04 | $-1.42 | $0 | 5 / 7 |
| 2026-08-05 | $-1.42 | $0 | 5 / 7 |
| 2026-08-06 | $-1.42 | $0 | 5 / 7 |
| 2026-08-07 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-08 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-09 | $-1.42 | $0 | 5 / 7 |
| 2026-08-10 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-11 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-12 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-13 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-14 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-15 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-16 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-17 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-18 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-19 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-20 | $-1.24 | $712,586 | 5 / 7 |
| 2026-08-21 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-22 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-23 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-24 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-25 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-26 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-27 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-28 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-29 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-30 | $-1.20 | $712,586 | 5 / 7 |
| 2026-08-31 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-01 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-02 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-03 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-04 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-05 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-06 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-07 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-08 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-09 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-10 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-11 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-12 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-13 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-14 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-15 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-16 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-17 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-18 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-19 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-20 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-21 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-22 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-23 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-24 | $-1.20 | $712,586 | 5 / 7 |
| 2026-09-25 | $-1.20 | $712,586 | 4 / 7 |
| 2026-09-26 | $-1.20 | $712,586 | 4 / 7 |
| 2026-09-27 | $-1.20 | $712,586 | 4 / 7 |
| 2026-09-28 | $-1.20 | $712,586 | 4 / 7 |
| 2026-09-29 | $-1.20 | $712,586 | 4 / 7 |
| 2026-09-30 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-01 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-02 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-03 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-04 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-05 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-06 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-07 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-08 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-09 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-10 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-11 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-12 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-13 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-14 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-15 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-16 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-17 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-18 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-19 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-20 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-21 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-22 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-23 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-24 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-25 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-26 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-27 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-28 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-29 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-30 | $-1.20 | $712,586 | 4 / 7 |
| 2026-10-31 | $-1.20 | $712,586 | 4 / 7 |
| 2026-11-01 | $-1.20 | $712,586 | 4 / 7 |
| 2026-11-02 | $-1.20 | $712,586 | 4 / 7 |
| 2026-11-03 | $-1.20 | $712,586 | 4 / 7 |
| 2026-11-04 | $-1.20 | $712,586 | 4 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.